A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

You may be eligible if

• Inclusion
• relapsing-remitting MS
• at least 1 exacerbation in preceding 2 years
• at least 1 MRI lesion
• stable for 2 months prior to dosing
• Exclusion
• progressive MS
• currently treated with an immunomodulatory therapy
• previously treated with an approved MS drug where treatment was discontinued for lack of efficacy
• active bacterial or viral infections